Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical, Inc.

Overview
Date Founded

2011

Headquarters

60 LEVERONI COURT, NOVATO, CA, 94949

Type of Company

Public

Employees (Worldwide)

740

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Contact Data
Trying to get in touch with decision makers at Ultragenyx Pharmaceutical, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder, President & Chief Executive Officer

Chief Financial Officer & Executive Vice President

General Counsel & Executive Vice President

Executive Vice President & Chief Commercial Officer

Executive Vice President & Chief Human Resources Officer

Chief Quality Operations Officer

Chief Business Officer & Executive Vice President

Chief Medical Officer & Executive Vice President

Senior Vice President, Corporate Controller & Principal Accounting Officer

Chief Technical Operations Officer & Executive Vice President

Board of Directors

Executive Chairman at Incarda Therapeutics, Inc.

Co-Founder at Seagen Inc.

President & Chief Executive Officer at H. Lundbeck A/S

Senior Advisor, Finance at Crinetics Pharmaceuticals, Inc.

President & Chief Operating Officer at Alector, Inc.

Former Vice President & General Manager-European Operations at BioMarin Pharmaceutical, Inc.

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Founder, President & Chief Executive Officer at Ultragenyx Pharmaceutical, Inc.

President, Chief Executive Officer & Director at Coda Biotherapeutics, Inc.

Paths to Ultragenyx Pharmaceutical, Inc.
Potential Connections via
Relationship Science
You
Ultragenyx Pharmaceutical, Inc.
Owners & Shareholders
Details Hidden

FGIM primarily provides advice with respect to equity investment strategies; however, they do not recommend a particular type of security. The firm’s strategies include core international/emerging market equities, international equity, international small- and mid-cap equity, balanced/asset allocation, managed risk and the Kaufmann Accounts. The Kauffman strategy invests in small, mid or large-cap stocks, utilizing a fundamental bottom-up process seeking growth companies and may invest in less developed or emerging markets.

Details Hidden

Alkeon Capital Management aims to achieve capital appreciation through investments primarily in long or short positions of publicly-traded and private companies across sectors globally. The firm employs a bottom-up, fundamentally driven, research-intensive approach to investing. On the long side, their investment program focuses on investments in the equity securities of companies that they believe are well positioned to benefit from demand for their products or services, including companies that can innovate or grow rapidly relative to their peers in their markets. On the short side, Alkeon Capital Management may affect short sales of securities when it believes that the market price of a security is above its estimated intrinsic or fundamental value.

Details Hidden

Rock Springs’ funds aims to generate capital appreciation through investments in a combination of public and private securities of companies in healthcare and healthcare-related industries. The funds focus mostly on public equities, utilizing a long-term, research-intensive approach to investing in healthcare and healthcare-related industries, with a particular emphasis on those companies and/or products that Rock Springs believes serve critical unmet needs.

Recent Transactions
Details Hidden

Ultragenyx Pharmaceutical, Inc. issued USD Commn Stock

Details Hidden

Ultragenyx Pharmaceutical, Inc. issued USD Common Stock

Details Hidden

Ultragenyx Pharmaceutical, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onUltragenyx Pharmaceutical, Inc. issued USD Commn Stock

Escrow Agent

Advised onUltragenyx Pharmaceutical, Inc. issued USD Commn Stock

Underwriter

Advised onUltragenyx Pharmaceutical, Inc. issued USD Commn Stock

Co-Chairman, Life Sciences Practice Group

Advised onUltragenyx Pharmaceutical, Inc. issued USD Commn Stock

Underwriter

Advised onUltragenyx Pharmaceutical, Inc. issued USD Commn Stock

Managing Director

Advised onUltragenyx Pharmaceutical, Inc. issued USD Commn Stock

Advisors & Consultants
Real Estate Agent

Co-Founder at Scripps Research Institute - Pearson Center for Alcoholism and Addiction Research

Advisor

Treasurer & Vice President at Dimension Therapeutics, Inc.

Legal Advisor

Partner at Fenwick & West LLP

Clients

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Key Stats and Financials As of 2019
Market Capitalization
$9.29B
Total Enterprise Value
$2.01B
Earnings Per Share
$-7.12
Revenue
$104M
Net Profit
$-403M
EBITDA
$-416M
EBITDAMargin
-400.75%
Total Debt
$352M
Total Equity
$654M
Enterprise Value / Sales
19.41x
TEVNet Income
-5x
Debt TEV
0.18x
Three Year Compounded Annual Growth Rate Of Revenue
820.42%
Non-Profit Donations & Grants
Investors
Details Hidden

FGIM primarily provides advice with respect to equity investment strategies; however, they do not recommend a particular type of security. The firm’s strategies include core international/emerging market equities, international equity, international small- and mid-cap equity, balanced/asset allocation, managed risk and the Kaufmann Accounts. The Kauffman strategy invests in small, mid or large-cap stocks, utilizing a fundamental bottom-up process seeking growth companies and may invest in less developed or emerging markets.

Details Hidden

NBIM is an active, conservative manager with a long-term outlook that aims to achieve the highest possible return on the Government Pension Fund Global within the investment mandate set by the Ministry of Finance, which owns the fund on behalf of the Norwegian people. The ministry determines the fund’s investment strategy, following advice from among others, NBIM and discussions in Parliament. The firm’s mandate defines the investment universe and the fund's strategic reference index. The Ministry of Finance has on a regular basis transferred capital to the fund from the Norwegian state's petroleum revenues. The fund's capital is invested abroad, to avoid overheating the Norwegian economy and to shield it from the effects of oil price fluctuations. The fund invests in international equity and fixed-income markets and real estate. It is invested in most markets, countries and currencies to achieve broad exposure to global economic growth. The investments are to produce a high long-term return. NBIM aims to achieve this this with an acceptable level of risk, as a responsible investor and through an efficient organization.

Details Hidden

CWI employs a long-term, value-oriented global investment approach and a multiple portfolio manager system that combines teamwork and individual accountability. The firm utilizes fundamental research to gather in-depth information on markets and companies around the world. They also employ a security-by-security approach to portfolio construction and emphasize long-term investments. Their strategies focus on determining the difference between the fundamental value of a company and its price in the marketplace. CWI offers a wide variety of equity, fixed-income and balanced investment strategies. Their strategies are categorized as global, multi-regional and regional investment strategies.

Suppliers
Kyowa Kirin Co., Ltd. Chemicals | Tokyo, Japan

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Co., Ltd. Chemicals | Osaka, Japan

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

IOI Corp. Bhd. Chemicals | Putrajaya, Malaysia

IOI Group's formation years were associated with real estate when it forayed into property development in 1982 followed by Oil Palm plantations in 1985. Today, IOI Group is internationally known as a leading global integrated palm oil player with operations stretching the entire palm value chain from seedlings to plantations to crop oil extraction to diverse value-added manufacturing across major continents - serving global markets in more than 65 countries. Close to its home-base in Malaysia, the Group is also prominently known as one of the leading property developer with significant investment holdings of prime real-estates. IOI Group employs more than 30,000 personnel of more than 23 different nationalities in 15 countries.

Competitors
Reneo Pharmaceuticals, Inc. Pharmaceuticals - San Diego, CA

Reneo Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm focuses on the development of therapies for patients with genetically defined orphan diseases. The company was founded by Michael G. Grey and Niall O'Donnell in 2014 and is headquartered in San Diego, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ultragenyx Pharmaceutical, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ultragenyx Pharmaceutical, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Ultragenyx Pharmaceutical, Inc..